AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026)
AtaiBeckley (ATAI) posted quarterly Cash from Financing Activities of $821000.0 for Q1 2026, down 98.62% year-over-year from $59.6 million in Q1 2025, and down 98.62% quarter-over-quarter from $59.6 million in Q1 2025.
Analysis
AtaiBeckley (ATAI) Cash from Financing Activities (2020 - 2026) Analysis & Trends
AtaiBeckley has reported Cash from Financing Activities for 6 years, with the latest figure at $59.7 million in Q3 2025.
- Quarterly Cash from Financing Activities rose 1120.76% year-over-year to $59.7 million in Q3 2025, while the trailing twelve-month figure through Sep 2025 was $127.3 million (up 4026.57% YoY) and the FY2024 annual result came in at $5.4 million, up 164.32% from the prior year.
- Cash from Financing Activities for Q1 2026 stood at $821000.0, down from $59.6 million in the prior quarter.
- The five-year high for Cash from Financing Activities was $59.6 million in Q1 2025, with the low at $821000.0 in Q1 2026.
- A 5-year average of $32.6 million and a median of $1.8 million in 2022 frame the typical range for Cash from Financing Activities.
- The sharpest annual moves came in 2023 and 2025: Cash from Financing Activities plunged 817.68% in 2023, then jumped 2279.45% in 2025.
- Over 5 years, Cash from Financing Activities stood at $1.7 million in 2021, then plunged by 153.51% to -$922000.0 in 2022, then slumped by 817.68% to -$8.5 million in 2023, then soared by 101.82% to $154000.0 in 2024, then surged by 38694.81% to $59.7 million in 2025.
- According to Business Quant data, Cash from Financing Activities over the past three periods registered $59.7 million, $7.8 million, and $59.6 million for Q3 2025, Q2 2025, and Q1 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Financing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.43 Bn | 130.58 Bn | 2.84 Bn | -426.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | -1.22 Bn |
| 3 | Argenx Se | 63.34 Bn | 58.15 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.98 Bn | 52.85 Bn | 52.00 Mn | 14.00 Mn |
| 5 | Revolution Medicines | 43.98 Bn | 43.98 Bn | - | 2.42 Bn |
| 6 | BeOne Medicines | 39.92 Bn | 34.82 Bn | 1.53 Bn | -6.05 Mn |
| 7 | Alnylam Pharmaceuticals | 35.42 Bn | 32.11 Bn | 992.69 Mn | 36.24 Mn |
| 8 | Royalty Pharma | 28.42 Bn | 27.58 Bn | - | -273.15 Mn |
| 9 | Insmed | 27.36 Bn | 26.20 Bn | 358.27 Mn | 27.18 Mn |
| 10 | AtaiBeckley | 1.61 Bn | 1.61 Bn | - | 59.74 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 2.64 Mn |
| Mar 31, 2026 | 821,000.00 |
| Sep 30, 2025 | 59.74 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Jun 30, 2025 | 7.76 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Mar 31, 2025 | 59.61 Mn |
| Dec 31, 2024 | 154,000.00 |
| Sep 30, 2024 | 4.89 Mn |
| Jun 30, 2024 | 326,000.00 |
| Dec 31, 2023 | -8.46 Mn |
| Jun 30, 2023 | -100,000.00 |
| Mar 31, 2023 | 206,000.00 |
| Dec 31, 2022 | -922,000.00 |
| Sep 30, 2022 | 19.78 Mn |
| Jun 30, 2022 | 1.79 Mn |
| Mar 31, 2022 | 132,000.00 |
| Dec 31, 2021 | 1.72 Mn |
| Sep 30, 2021 | 3.88 Mn |
| Jun 30, 2021 | 373.76 Mn |